financetom
Business
financetom
/
Business
/
July business figures disappoint private life insurance companies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
July business figures disappoint private life insurance companies
Aug 14, 2019 7:27 AM

The July business figures failed to bring any cheer to the listed private life insurance companies on premiums and market share growth.

As per the data published by the Insurance Regulatory and Development Authority of India or IRDAI, HDFC Life in the month of July lost its market share by 51 basis points between January to July 2019 to 6.56 percent.

July premium growth for HDFC Life stood at 25.8 percent against 42 percent in Q1FY20. There was slowdown seen on the Annual Premium Equivalent or APE front as well which in the month of July grew at 57.7 percent against 62.72 percent in Q1FY20.

ICICI Prudential took the maximum damage with company’s July APE showing a contraction of 1.3 percent against a growth of 1 percent in Q1FY20. The company also lost its market share by 102 bps in the period between January to July 2019. The market share now stands at 3.86 percent.

Max Life has been an exception in an otherwise dull market. The company in the month of July grew its premium by 38.3 percent against a growth of 24.6 percent in Q1FY20.

Major disappointment also came in for SBI Life in the month of July. Company’s market July premium grew by 8 percent against growth of 35 percent in Q1FY20.

Overall, the private life insurance space lost market share by 6.9 percent with its premium in the month of July growing at 15.46 percent against 27 percent in Q1FY20.

The Life Insurance Corporation of India (LIC) held on to its market share of 73.1 percent at the end of July 2019. The premium for the life insurance major in the month of July grew at 3.1 percent with its APE growing at 10.4 percent in the month of July.

First Published:Aug 14, 2019 4:27 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Mueller Industries Keeps Quarterly Dividend at $0.25 a Share, Payable Sept. 19 to Holders of Record on Sept. 5
--Mueller Industries Keeps Quarterly Dividend at $0.25 a Share, Payable Sept. 19 to Holders of Record on Sept. 5
Jul 31, 2025
03:31 PM EDT, 07/31/2025 (MT Newswires) -- Price: 85.67, Change: -1.83, Percent Change: -2.09 ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Shake Shack Shares Slump on Downbeat Quarterly Revenue Guidance, Same-Store Sales Miss
Shake Shack Shares Slump on Downbeat Quarterly Revenue Guidance, Same-Store Sales Miss
Jul 31, 2025
03:35 PM EDT, 07/31/2025 (MT Newswires) -- Shake Shack ( SHAK ) shares tumbled intraday Thursday after the burger chain issued a downbeat third-quarter revenue outlook following a same-store sales miss in the second quarter. For the ongoing quarter, the company expects revenue of $358 million to $364 million, Chief Financial Officer Katherine Fogertey said on an earnings conference call,...
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
Jul 31, 2025
The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. ( ALNY ) continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam’s recent performance highlights the company’s strong position in the competitive landscape. ALNY stock is testing its 52-week high. Check the latest price here. Alnylam Pharmaceuticals (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved